4//SEC Filing
BIOS Fund I, LP 4
Accession 0001104659-24-029534
CIK 0001763950other
Filed
Feb 28, 7:00 PM ET
Accepted
Feb 29, 9:54 PM ET
Size
41.8 KB
Accession
0001104659-24-029534
Insider Transaction Report
Form 4
BIOS Fund II QP, LP
10% Owner
Transactions
- Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP)
Holdings
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
BIOS Fund II NT, LP
10% Owner
Transactions
- Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP)
Holdings
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
Bios Equity Partners, LP
10% Owner
Transactions
- Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP)
Holdings
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
Fletcher Aaron G.L.
10% Owner
Transactions
- Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP)
Holdings
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
BIOS Fund I, LP
10% Owner
Transactions
- Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP)
Holdings
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
BIOS Fund I QP, LP
10% Owner
Transactions
- Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP)
Holdings
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
BIOS Fund II, LP
10% Owner
Transactions
- Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP)
Holdings
- 26,093(indirect: By BP Directors, LP)
Common Stock
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
BIOS Capital Management, LP
10% Owner
Transactions
- Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP)
Holdings
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
BIOS Advisors GP, LLC
10% Owner
Transactions
- Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP)
Holdings
- 26,093(indirect: By BP Directors, LP)
Common Stock
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
Bios Equity Partners II, LP
10% Owner
Transactions
- Sale
Common Stock
2024-02-28$4.85/sh−6,909$33,509→ 62,088 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-29$4.87/sh−1,832$8,922→ 60,256 total(indirect: By Bios Fund II NT, LP) - Sale
Common Stock
2024-02-27$4.40/sh−34,731$152,816→ 515,412 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-28$4.85/sh−51,608$250,299→ 463,804 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-29$4.87/sh−13,686$66,651→ 450,118 total(indirect: By Bios Fund II QP, LP) - Sale
Common Stock
2024-02-27$4.40/sh−10,620$46,728→ 157,797 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-28$4.85/sh−15,780$76,533→ 142,017 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-29$4.87/sh−4,185$20,381→ 137,832 total(indirect: By Bios Fund II, LP) - Sale
Common Stock
2024-02-27$4.40/sh−4,649$20,456→ 68,997 total(indirect: By Bios Fund II NT, LP)
Holdings
- 371,950(indirect: By Bios Fund I, LP)
Common Stock
- 217,553(indirect: By Bios Fund I QP, LP)
Common Stock
- 26,093(indirect: By BP Directors, LP)
Common Stock
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. On February 27, 2024 each of Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $4.35 to $4.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to (3) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. On February 28, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $4.60 to $5.21, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. On February 29, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $4.62 to $5.33, inclusive.
- [F4]Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
- [F5]Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
- [F6]For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Documents
Issuer
Lantern Pharma Inc.
CIK 0001763950
Entity typeother
IncorporatedTX
Related Parties
1- filerCIK 0001697316
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Feb 29, 9:54 PM ET
- Size
- 41.8 KB